Benefits of SCIg Therapy for CIDP Patients
Subcutaneous immunoglobulin (SCIg) therapy is transforming the management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with its advantages over traditional intravenous methods. It offers increased patient independence, reduced systemic side effects, and cost-effectiveness through self-administration and fewer hospital visits. Understanding these benefits highlights its potential as a personalized and efficient therapeutic option for CIDP patients. Revolutionary […]
3 minute read